stockrow
Monday 9 November 2026
Export ICCM’s income statement to Excel — free account
IceCure Medical Ltd.
ICCMIceCure Medical Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $3.4 million, up 2.67% from fiscal 2024.
- Revenue
- −0.69%
- EPS
- −2,068.2%
- Free cash flow
- +3.88%
- Total debt
- −64.4%
Quarter to June 2026, against a year earlier
0.68
0.01
−1.45%
Follow ICCM
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 0.00 | — |
P/S ratio |
— | — | 8.20 | — | |
P/FCF ratio |
— | — | 0.00 | — | |
P/Operating CF |
— | — | (5.18) | — | |
P/B ratio |
— | — | 2.60 | — | |
Price to Tangible BV |
— | — | 2.60 | — | |
EV/Sales |
— | — | 5.24 | — | |
EV/EBITDA |
— | — | 0.00 | — | |
EV/Operating CF |
— | — | (0.68) | — | |
EV/FCF |
— | — | (0.68) | — | |
Quick Ratio |
1.76 | 1.91 | 1.75 | 2.15 | |
Current Ratio |
2.38 | 2.61 | 2.52 | 2.88 | |
Net Debt/EBITDA |
0.00 | 0.00 | 1.94 | 0.00 | |
Debt/Assets |
0.16% | 0.09% | 0.04% | 0.12% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.22 | 0.00 | |
Operating CF/Net income |
0.00 | — | 1.00 | 0.00 | |
Capex/Depreciation |
(0.14) | — | (0.74) | (0.14) | |
Research and Development Expense of Revenue |
— | — | 242.70% | — | |
Selling, General and Administrative Expense of Revenue |
— | — | 255.87% | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 19.76% | 0.00% | |
Graham Net Nets |
— | — | 0.33 | — | |
Graham Number |
— | — | 0.00 | — | |
Earnings Yield |
— | — | (67.47%) | — | |
Free Cash Flow Yield |
— | — | (93.95%) | — | |
Revenue per Share |
— | — | 0.37 | — | |
Operating CF per Share |
0.00 | — | (1.74) | 0.00 | |
Capex per Share |
0.00 | — | (0.02) | 0.00 | |
Free Cash Flow per Share |
0.00 | — | (1.76) | 0.00 | |
Cash per Share |
0.00 | 0.00 | 3.31 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 3.47 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 3.47 | 0.00 | |
Free Cash Flow |
(9.59) | — | (4.32) | (3.89) | |
Working Capital |
7.91 | 7.78 | 7.32 | 10.86 | |
Capital Expenditures |
(0.03) | — | (0.05) | (0.01) | |
Net Current Asset Value |
7.88 | 7.77 | 7.32 | 10.84 | |
EV/EBIT |
— | — | 0.00 | — | |
Capex to Sales |
0.00 | — | 0.06 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | — | |
| Other line items | |||||
Average Receivables |
0.12 | 0.28 | 0.29 | 0.27 | |
Average Payables |
1.20 | 1.05 | 0.97 | 1.40 | |
Average Inventory |
2.35 | 2.31 | 2.34 | 2.44 | |
Average Assets |
15.18 | 13.23 | 12.20 | 14.15 | |
Average Common Equity |
9.68 | 7.98 | 7.25 | 7.39 |
Columns are period end dates · fundamentals updated 26 Oct 2026